Overview

Study of an Extended-Release, Crystalline Formulation of Recombinant Human Growth Hormone (ALTU-238) in Growth Hormone Deficient Adults to Determine Pharmacokinetics, Pharmacodynamics, and Drug Safety

Status:
Completed

Trial end date:
2006-06-01

Target enrollment:

Participant gender:

Summary

ALTU-238 is a long acting crystalline formulation of recombinant human growth hormone (rhGH) that is being developed for the treatment of growth hormone deficiency in adults and children. ALTU-238 is designed to require fewer injections than the currently available formulations of rhGH.

Phase:

Phase 2

Details

Lead Sponsor:

Altus Pharmaceuticals

Treatments:

Hormones